October 16, 2023
Atlanta, GA – October 16, 2023 – The CEO of OncoSpherix, Inc, Dr. Margaret K. Offermann, MD, PhD, is delivering a keynote address at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM. Her presentation is entitled “Critical Decisions for Advancing Small Molecule Hypoxia-Inducible Factor Inhibitors for Advanced Cancer”. She will share evidence using preclinical models that OncoSpehrix’s HIF inhibitors are effective at inhibiting primary tumor growth and metastases in many forms of cancer and show synergy when given in combination with several classes of systemic cancer treatment.
About OncoSpherix:
OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supplies, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candidate has been shown in mouse models to reduce primary tumor growth, inhibit metastasis, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). OncoSpherix intends to advance its lead candidate in one or more of these indications, in combination with agents that show therapeutic synergy while being well-tolerated.as part of the combination.
Company Contact:
Allan Valmonte
VP of Business Operations
Source: OncoSpherix, Inc.